COBO Technologies and Cardea Bio partner to bring solutions to challenges with the precision of Genome editing.

The partners have agreed to co-develop and market a portfolio of CRISPR QC products and services for quality control (QC) of CRISPR research, agricultural, and pre-clinical programs.

"COBO Technologies and Cardea Bio partner to bring solutions to challenges with the precision of Genome editing. The partners have agreed to co-develop and market a portfolio of CRISPR QC products and services for quality control (QC) of CRISPR research, agricultural, and pre-clinical programs. Over the longer-term, the parties aim to develop a COBO branded QC device based on Cardea’s CRISPR-Chip™ QC technology for use before and after genome-editing in the pre-clinical setting"

Read the full Press Release here.

-------------------------------------------------------------------------------------------------------------------------------------------------------------

COBO Technologies is a fast-growing CRO specialised in services and products for quality control of genome editing applications in research and clinical fields. The company supports customers globally with detailed DNA mutation analysis and complexed proteome expression profiling of cells, plants or animals modified with genome editing tools such as CRISPR-Cas9, ZFNs, Meganucleases and TALENs.

Downloads

PressRelease_COBO-Cardea_Jan2020.pdf

Tags

Corporate NewsCRISPRCRISPRQCGenome EditingPress ReleaseQuality Control Genome Editing